Company Overview
Snapshot
Founded in January 2017 by Ofer Mandelboim and Pini Tsukerman, Nectin Therapeutics operates with 11–50 employees. The company has raised $36 million across 6 funding rounds from 7 investors.
Business overview
Nectin Therapeutics is a biotechnology company focused on developing next-generation immune-oncology (IO) therapies for cancer patients. The company's core technology involves a diverse pipeline of targeted antibodies based on nectin pathways, designed to overcome inhibitory pathways used by tumors and enable immune cells to destroy cancer cells effectively. Additionally, it develops CAR-T and -NK drivers that specifically target tumor cells in various indications, including hard-to-treat cancers. Nectin Therapeutics operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, targeting patients and pharmaceutical industries.
Strategic signal
In June 2026, Nectin Therapeutics reported encouraging Phase 1 results for its NTX1088 therapy in combination with KEYTRUDA (pembrolizumab) at ASCO 2026. This positive clinical data provides a strong validation of the company's lead drug candidate and its potential in treating advanced solid tumors, signaling significant progress in its therapeutic development and potential for future partnerships or accelerated clinical pathways.
Log in to access full profile ›Company Intelligence Q&A
- What clinical trial progress has Nectin Therapeutics announced recently?
- In June 2026, Nectin Therapeutics reported encouraging Phase 1 results for NTX1088 in combination with KEYTRUDA (pembrolizumab) at ASCO 2026, indicating positive advancements in their clinical development.
- Which investor participated in Nectin Therapeutics' funding round in May 2023?
- In May 2023, Myeloma Investment Fund invested in.
- What was the collaboration announced by Nectin Therapeutics in February 2023?
- In February 2023, Nectin Therapeutics announced a collaboration with Merck on a clinical trial for their anti-PVR antibody NTX1088 in combination with KEYTRUDA (pembrolizumab) for patients with locally advanced and metastatic solid tumors.
- Which investors led the December 2022 funding round for Nectin Therapeutics?
- In December 2022, Nectin Therapeutics secured funding with.